囤抗病毒药物应对大流行：制造商储备计划的作用。

Stockpiling anti-viral drugs for a pandemic: the role of Manufacturer Reserve Programs.

机构信息

Department of Economics, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218-2685, USA.

出版信息

J Health Econ. 2010 May;29(3):438-44. doi: 10.1016/j.jhealeco.2010.02.004. Epub 2010 Mar 16.

DOI:10.1016/j.jhealeco.2010.02.004

PMID:20236719

Abstract

To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.

摘要

为了促进医院等非政府组织储备抗病毒药物，药品制造商推出了制造商储备计划，该计划每年收取一定费用，在发生严重流感疫情时提供购买权。我们的研究表明，这些计划提高了药品制造商的利润，但可能会增加或减少大流行前储备抗病毒药物的数量。